Premium
Value of R2* obtained from T2*‐weighted imaging in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy
Author(s) -
Li Xiang Sheng,
Fan Hong Xia,
Fang Hong,
Song Yun Long,
Zhou Chun Wu
Publication year - 2015
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.24837
Subject(s) - medicine , chemoradiotherapy , receiver operating characteristic , oncology , radiology , nuclear medicine , radiation therapy
Background To prospectively investigate the value of R2* in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy. Methods Sixty‐five patients with biopsy‐proven cervical squamous carcinoma were enrolled in our study. All these subjects underwent multi‐echo T2*‐weighted MR imaging on a 3.0 Tesla MR scanner, and tumor R2* was calculated. The patients were divided into the responders and the nonresponders according to treatment effect. Tumor R2* values of these two groups were compared. The relationship between tumor R2* and prognosis after therapy was analyzed. Results The responder group had lower R2* value than the nonresponder group ( P = 0.02). The area under the receiver operating characteristics curve for tumor R2* in discriminating responders from nonresponders was 0.769. A cutoff value of 23.87 Hz for tumor R2* resulted in a sensitivity of 78.3% and a specificity of 67.6%. The low R2* group (≤28.37 Hz) had longer median progression‐free survival period and overall survival period ( P = 0.01, 0.03). Multivariate analysis showed that tumor R2* was a significant prognostic factor for progression‐free survival and overall survival (adjusted hazards ratio = 5.34, 4.78; P = 0.02, 0.01). Conclusion R2* value obtained from T2*‐weighted imaging, as an imaging biomarker, may be an important predictor for the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy. J. Magn. Reson. Imaging 2015;42:681–688.